Navigation Links
Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis
Date:10/22/2007

WASHINGTON, Oct. 22 /PRNewswire/ -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day and six- month follow-up, reported Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, in Washington, D.C.

Specifically, six-month clinical follow-up data from the 193-patient, single-center, prospective, single-blind study called TRIAS HR Pilot indicate:

-- No statistically significant difference in the rate of major adverse

cardiac events (MACE)

-- At six-month follow-up, the majority of patients who received a Genous

stent were on single antiplatelet therapy, while the majority of

patients who received a Taxus stent were still on dual antiplatelet

therapy

-- One acute stent thrombosis in the Genous arm, while there was one acute,

one subacute and one late stent thrombosis in the Taxus arm

-- More instances of non-target vessel revascularization (non-TVR) in the

Taxus arm

"The much-needed alternative to drug-eluting stents may not be the next- generation drug-eluting stents," said de Winter. "Genous is a very promising, innovative device with a wide range of applications for physicians and many benefits to patients. The results of our pilot study fully support our rationale for the large-scale TRIAS study that will compare Genous to both drug-eluting and bare metal stents."

For the TRIAS HR Pilot, high risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than 2.8 mm) and/or long lesions (greater than 20 mm) and/or chronic total occlusions.

Genous is co
'/>"/>

SOURCE Academic Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
2. Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study
3. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
6. Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA
7. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
8. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
9. ISTA Pharmaceuticals Announces Positive Preliminary Results from Ecabet Sodium Phase IIb Study
10. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
11. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 Research and Markets ... "Will Theranos Turn the Lab Industry Upside Down?" ... received much praise along with a healthy dose of ... with their potentially disruptive laboratory solution. Behind all of ... Has Theranos scaled microfluidic technology across a comprehensive menu ...
(Date:5/4/2015)... (NASDAQ: LMNX ) today announced financial results for the ... include the following: , Consolidated first quarter revenue ... quarter of 2014. , First quarter assay revenue of ... of 2014. , Consolidated gross profit margin was 70 ... net income for the first quarter was $7.5 million or ...
(Date:5/4/2015)... , May 4, 2015  Neurocrine Biosciences, Inc. (NASDAQ: ... Aurora has joined the company as Vice President, ... to welcome Dr. Bill Aurora to the ... Kevin Gorman , President and Chief Executive Officer ... scientific exchange and outreach coupled with his extensive network ...
Breaking Medicine Technology:Will Theranos Turn the Lab Industry Upside Down? 2Luminex Corporation Reports First Quarter 2015 Results 2Luminex Corporation Reports First Quarter 2015 Results 3Luminex Corporation Reports First Quarter 2015 Results 4Luminex Corporation Reports First Quarter 2015 Results 5Luminex Corporation Reports First Quarter 2015 Results 6Luminex Corporation Reports First Quarter 2015 Results 7Luminex Corporation Reports First Quarter 2015 Results 8Luminex Corporation Reports First Quarter 2015 Results 9Luminex Corporation Reports First Quarter 2015 Results 10Luminex Corporation Reports First Quarter 2015 Results 11Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 2Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 3
(Date:5/5/2015)... Washington, DC (PRWEB) May 05, 2015 ... Amplify Hope Initiative, a new study aimed at determining ... disease patients. RG is an international non-profit providing rare ... genomics sequencing technology, connections to scientists and researchers, and ... or crowdfunding. , “I am excited to see how ...
(Date:5/5/2015)... 2015 For the growing list of high ... data loggers. This data logger series is based ... for optimum performance throughout exposure to high temperatures and submersion ... are capable of storing up to 32,700 readings and feature ... one year or longer. All data loggers in the HiTemp140 ...
(Date:5/5/2015)... 2015 Sheltering Arms held its annual ... Frazier and Cravath, Swaine & Moore LLP for their ... The event was co-chaired by Vanguard sponsors Morgan Stanley ... Chapter” highlighted Sheltering Arms’ significant growth in New York ... February 2015. Formerly Episcopal Social Services, Sheltering Arms has ...
(Date:5/5/2015)... San Francisco, California (PRWEB) May 05, 2015 ... company based in San Francisco, leads an international initiative ... in order to extend the human lifespan. Scientists ... clocks inherent to women, from the initiation of her ... reveal a possible mechanism for aging and, ultimately, extend ...
(Date:5/5/2015)... ON (PRWEB) May 05, 2015 Crawford Technologies ... Award’ from the Colorado Chapter of the Business ... in 2014. The Gold Key Award was presented to the ... Museum of Nature and Science with over 300 people in ... website in March 2014 represented a shift in focus ...
Breaking Medicine News(10 mins):Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6Health News:Sheltering Arms Honors Walt "Clyde" Frazier and Cravath, Swaine & Moore LLP at Annual Gala 2Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 3
... of multiple risk factors at once, , , WEDNESDAY, Feb. ... are already showing signs of some kidney damage may be ... multiple risk factors at once. , That,s the conclusion ... issue of the New England Journal of Medicine , ...
... Foundation has announced the names of the recipients of its ... Dr. Inder Verma is the prize recipient for biomedical science; ... The Vilcek Foundation Prizes are awarded annually to foreign-born ... , In explaining the motivation for the awards, ...
... Preliminary study finds some benefit from calcium channel blockers ... calcium channel blockers to control their high blood pressure ... say long-term use of the drugs also might cut ... the findings are far from definitive and not yet ...
... seek restatement of Beth Israel Deaconess,Medical Center audit, ... the same Sarbanes-Oxley standards used by Staples and other,publicly ... Beth Israel Deaconess,Medical Center (BIDMC), according to labor group ... of Samtex and a director of,Massachusetts-based Virtusa Corporation as ...
... Board of Directors Dashboard, WASHINGTON, Feb. 6 ... (OIG) for the Department of Health,and Human Services (HHS) ... and opportunities for the boards of directors of,long-term care ... of Care Dashboard is a management tool that may ...
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,that ... 66th Annual Meeting,of the American Academy of Dermatology ... to the Academy, Dr. Sadick, a prominent New ...
Cached Medicine News:Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 3Health News:Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science 2Health News:Blood Pressure Drugs Might Prevent Parkinson's 2Health News:Blood Pressure Drugs Might Prevent Parkinson's 3Health News:Staples Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:OIG and HCCA Issue Government-Industry Roundtable Report 2Health News:Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2
The Calcanea® calcaneal fracture fixation plate is specifically designed to treat fractures of the hind foot. Its unique combined features include variable thickness and angle-stabilized and/or ...
... best of todays most popular refractive surgeries, LASIK ... to cut the patients cornea or apply alcohol ... EpiLift System is used, the epithelium the ... separated, at a natural division point in the ...
... The Titan Procedure is a safe, ... light source to tighten skin and ... Titan heats the dermis to cause ... through continuous cooling. In addition, Titan ...
... dedicated, plastic, single use, disposable device that ... localization sites, after the needle is in ... localization needle from accidental movement by contact, ... surgery. ,Increase patient confidence in your staff ...
Medicine Products: